News | April 18, 2021
Lonza and Immunitas announce manufacturing agreement
Lonza's Ibex Design end-to-end offering will cover the development stages of IMT-009 from development candidates through early clinical studies
Lonza's Ibex Design end-to-end offering will cover the development stages of IMT-009 from development candidates through early clinical studies
The IPO comprises a fresh issue of up to Rs. 11,600 million and an offer for sale of up to 7,305,245 equity shares of Rs. 2 each of Glenmark Life Sciences by Glenmark Pharmaceuticals
Acquisition of A&C expands Aceto’s Western manufacturing footprint
Presently, IMPCL is manufacturing 656 classical Ayurvedic, 332 Unani and 71 proprietary Ayurvedic medicines for the various diseases spectrum
Indian government is expecting pharmaceutical industry to fetch incremental sales worth Rs. 294,000 crore and exports up to Rs. 196,000 crore by FY 2027-28
The company is pursuing specific goals in the areas of science and technology, value chain as well as climate and the environment.
The company has received a certificate of Good Manufacturing Practice compliance from the Medicines & Healthcare products Regulatory Agency (MHRA) UK
The approval is for Ibrutinib tablets 560 mg, 420 mg, 280 mg and 140 mg strengths
The merger is in line with Solara’s strategy of accelerating growth via appropriate inorganic actions
Both the vaccines have been extensively tested by IVRI for safety and potency and have been found to provide 100% protection
Subscribe To Our Newsletter & Stay Updated
